Table 1.

Associations and comparisons between CHD4 expression and clinicopathological factors in 172 rectal cancer patients who were receiving neoadjuvant CCRT. High expression of CHD4 was significantly associated with pre-Tx tumor status (p < 0.001), pre-Tx lymph node metastasis (p < 0.001), post-Tx tumor status (p < 0.001), post-Tx lymph node metastasis (p < 0.001), vascular invasion (p = 0.042), and tumor regression grade (p = 0.001).

Parameter		No.	CHD4 Expression		p-Value
			Low Exp.	High Exp.
Gender	Male	108	60	48	0.194
	Female	64	29	35
Age	<70	106	61	45	0.054
	≥70	66	28	38
Pre-Tx tumor status (Pre-T)	T1–T2	81	55	26	<0.001 *
	T3–T4	91	34	57
Pre-Tx nodal status (Pre-N)	N0	125	77	48	<0.001 *
	N1–N2	47	12	35
Post-Tx tumor status (Post-T)	T1–T2	86	57	29	<0.001 *
	T3–T4	86	32	54
Post-Tx nodal status (Post-N)	N0	123	76	47	<0.001 *
	N1–N2	49	13	36
Vascular invasion	Absent	157	85	72	0.042 *
	Present	15	4	11
Perineural invasion	Absent	167	88	79	0.149
	Present	5	1	4
Tumor regression grade	Grade 0–1	37	11	26	0.001 *
	Grade 2–3	118	64	54
	Grade 4	17	14	3

*, statistically significant.